Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis

Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis

BackgroundSacituzumab govitecan (SG) is an antibody-drug conjugate (ADC) that targets trophoblast cell-surface antigen 2 and is conjugated to SN-38, a potent topoisomerase I inhibitor. SG has demonstrated promising activity against various solid tumors. However, comprehensive evaluations of its effi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yaping Zhang, Jian Chen, Xiaoyan Wang, Hui Wang, Xiaoli Chen, Jianfeng Hong, Hongming Fang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Oncology
Subjects:	Sacituzumab govitecan solid tumors breast cancer lung cancer urothelial cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1624386/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis
by: Maria Inez Dacoregio, et al.
Published: (2025-02-01)

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study
by: E. Fountzilas, et al.
Published: (2025-03-01)

Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine
by: Saif Khan, et al.
Published: (2024-12-01)

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan
by: Megan H. Wong, et al.
Published: (2024-08-01)

Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis
by: George W. Jr. Sledge, et al.
Published: (2025-08-01)

Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer
by: Hope S. Rugo, et al.
Published: (2025-03-01)

Last Resort? Rationale for Comprehensive Molecular Analysis in Treatment-Refractory R/M HNSCC: A Case Report of Remarkable Response to Sacituzumab Govitecan Following Molecular and Functional Characterization
by: Henrike Barbara Zech, et al.
Published: (2025-05-01)

Partial Response Achieved in a Case of Metastatic Triple-Negative Breast Cancer Based on the Patient-Derived Tumor Organoids
by: Liu Y, et al.
Published: (2025-07-01)

Multimodal evaluation of cerebrospinal fluid from breast cancer leptomeningeal metastases using circulating tumor cell detection, single-cell sequencing, and proteomics
by: Elnaz Rahbarlayegh, et al.
Published: (2025-07-01)

Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids
by: Wu Ying, et al.
Published: (2025-07-01)

Progress of antibody–drug conjugates in the treatment of locally advanced or metastatic urothelial carcinoma: opportunities and challenges
by: Fanhao Zeng, et al.
Published: (2025-05-01)

Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer
by: Jayakumar R. Nair, et al.
Published: (2024-12-01)

A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan
by: Takamichi Ito, et al.
Published: (2025-01-01)

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies
by: Quchang Ouyang, et al.
Published: (2025-06-01)

The role of circulating tumor DNA (ctDNA) in urothelial cancers
by: Jeanny B. Aragon-Ching
Published: (2025-05-01)

Unraveling the complex role of tumor-associated neutrophils within solid tumors
by: Yingxin Wang, et al.
Published: (2025-05-01)

CLINICAL CASE OF TREATMENT OF INVASIVE UROTHELIAL CANCER OF THE UPPER URINARY TRACT. PROBLEMS OF COMBINED TREATMENT
by: A. A. Klimenko, et al.
Published: (2018-03-01)

Brain metastasis from renal urothelial carcinoma successfully treated by metastasectomy
by: Wen-Kuei Fang, et al.
Published: (2018-01-01)

MMP1-induced NF-κB activation promotes epithelial–mesenchymal transition and sacituzumab govitecan resistance in hormone receptor-positive breast cancer
by: Letian Chen, et al.
Published: (2025-04-01)

Uncommon presentation of transitional cell carcinoma: A case report of hand involvement
by: Zahra Sanei‐Far, et al.
Published: (2024-09-01)

Comparison of the oncological and functional outcomes among patients with high‐risk upper tract urothelial cancer undergoing segmental ureterectomy based on tumour location
by: Maksym Pikul, et al.
Published: (2025-06-01)

Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis
by: Wenjun Fang, et al.
Published: (2025-12-01)

Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study
by: Junya Arima, et al.
Published: (2025-08-01)

A histopathological and epidemiological study of urothelial carcinoma at a tertiary care centre in Peshawar, Pakistan
by: Saria Saeed, et al.
Published: (2024-05-01)

Histomorphological pattern of lesions of cystoscopic bladder biopsies in a tertiary center in Nepal- A retrospective descriptive study
by: Amar Narayan Shrestha, et al.
Published: (2022-09-01)

Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045
by: Anke Richters, et al.
Published: (2025-01-01)

The role of immunohistochemical analysis in determining the molecular subtypes of bladder cancer
by: M. V. Berkut, et al.
Published: (2024-12-01)

Lung cancer in solid organ transplant recipients
by: A. V. Nikulin, et al.
Published: (2022-01-01)

Rehabilitation and physical activity during treatment of various types of cancer
by: Weronika Woźniak, et al.
Published: (2025-05-01)

Differential cardiac impacts of hematological malignancies and solid tumors: a histopathological and biomarker study
by: Michael H. Udin, et al.
Published: (2024-12-01)

Estimating Cancer Penetrance in Carriers of BRCA2 Pathogenic Variants Using Cancer‐Specific Polygenic Scores
by: Brendan Prassas, et al.
Published: (2025-06-01)

Comparison of 5-year incidence of subsequent primary malignancies among patients with melanoma vs basal cell carcinoma: A gender-stratified propensity score-matched cohort study
by: Donna Pham, MS, et al.
Published: (2025-10-01)

Case report: Long-term response to a combination of immune checkpoint inhibitors as a single treatment for multiple synchronous cancers: a case study
by: Nour Ghammem, et al.
Published: (2024-12-01)

Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1–4 mutated solid tumors
by: Jiyu Huang, et al.
Published: (2025-08-01)

CLINICAL CASE OF MULTIMODALITY TREATMENT OF METASTATIC BLADDER CANCER
by: A. V. Lykov, et al.
Published: (2020-01-01)

The most common forms of cancer and oncogenic papillomaviruses
by: G. M. Volgareva
Published: (2024-06-01)

CD44 and Its Role in Solid Cancers – A Review: From Tumor Progression to Prognosis and Targeted Therapy
by: João Martins Gama, et al.
Published: (2025-03-01)

Diffuse large B-cell lymphoma combined with two solid tumors: a case report
by: Xiufang Zhang, et al.
Published: (2025-06-01)

Protocol for pathologic examination of bladder cancer according to the updates of the 5th edition of the WHO classification (2022): radical cystectomy specimens
by: N. S. Bondarenko, et al.
Published: (2025-04-01)

High-grade non-muscle invasive urothelial carcinoma in dogs and humans share specific expression of integrin α5β1
by: Roberta Lucianò, et al.
Published: (2025-05-01)